Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Animal Intestinal Health Market: Antibiotic Stewardship Alternatives and Gut Microbiome Science to Drive Market Growth

The global animal intestinal health market was valued at USD 5.2 billion in 2025 and is projected to reach USD 10.84 billion by 2035, expanding at a CAGR of 8.5%. Encompassing probiotics, prebiotics, phytogenic feed additives, organic acids, enzymes, postbiotics, and gut microbiome-modulating products, the market addresses gastrointestinal health, microbiome integrity, and enteric disease burden in livestock and companion animals. The market is growing primarily as an alternative to antibiotic growth promoters following the EU ban on prophylactic antibiotic use and the U.S. Veterinary Feed Directive requiring veterinary oversight for medicated feed antibiotic use.

Livestock is the dominant animal type by market volume, with poultry and swine the primary species driving intestinal health product adoption — where enteric disease (necrotic enteritis in broilers, post-weaning diarrhea in piglets) causes the largest production losses that intestinal health products target. Companion animal probiotics are the fastest-growing segment, driven by pet humanisation extending human gut health awareness to dogs and cats, with veterinary-grade probiotic products like Zoetis’s FortiFlora (Purina partnership) serving the growing companion animal microbiome market.

Executive Snapshot

What is the confirmed market size and growth trajectory for the animal intestinal health market?
The market was valued at USD 5.2 billion in 2025 and is projected to grow at a CAGR of 8.5% to USD 10.84 billion by 2035. Probiotics are the dominant product category. Poultry is the dominant livestock species by volume. Companion animal probiotics are the fastest-growing segment. North America and Europe lead; Asia-Pacific grows fastest from poultry and swine intensification.

How does antimicrobial stewardship regulation create structural demand for intestinal health alternatives?
EU Regulation 2019/6 restricting prophylactic antibiotic use in livestock — combined with the historic 2006 EU ban on antibiotic growth promoters — has created a regulatory void in European livestock production where intestinal health additive alternatives (probiotics, phytogenics, organic acids) have grown to fill the production performance gap. U.S. VFD requirements creating veterinary oversight for medicated feed antibiotics similarly direct livestock producers toward alternatives that maintain production without antibiotic inputs.

What scientific basis underpins the intestinal health product market?
The gut microbiome’s central role in immune system development, nutrient utilisation efficiency, and resistance to enteric pathogen colonisation is now supported by substantial peer-reviewed literature documenting that microbiome composition predicts production performance in poultry and swine. Probiotics containing Lactobacillus, Bacillus, and Enterococcus strains, phytogenic extracts with antimicrobial plant compounds, and organic acids reducing gut pH to inhibit pathogen growth all show statistically significant production performance benefits that sustain commercial adoption.

How does the companion animal probiotic market differ from the livestock segment?
Companion animal probiotics are positioned as wellness products addressing digestive health, immune support, and antibiotic-associated diarrhea — sold through veterinary prescription, veterinary recommendation, and direct pet retailer channels at per-dose prices of USD 1 to USD 3 reflecting the premium companion animal health product pricing above livestock volumes. The companion animal probiotic market is growing fastest because pet humanisation extends human gut health wellness culture directly to dog and cat health management.

How does Elanco’s innovation commitment support the intestinal health market?
Elanco’s farm animal portfolio — serving cattle, poultry, swine, and sheep — and its heritage of innovation dating from 1954 create the research and commercial infrastructure that developing intestinal health product categories require for responsible introduction into global livestock production systems. Elanco’s Go Beyond commitment to farmers extends to providing reliable products that maintain production performance within antimicrobial stewardship frameworks.

What is the role of phytogenic feed additives as the fastest-growing intestinal health category?
Phytogenic feed additives — containing essential oils (oregano, thyme, cinnamon), herb and plant extracts with antimicrobial and anti-inflammatory properties — are growing fastest because they address the production performance gap left by antibiotic growth promoter removal without triggering resistance concerns, and because they carry a natural product positioning that appeals to clean-label consumer preferences in the food supply chain above or downstream from the livestock producer.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Animal Intestinal Health Market

  • EU livestock antibiotic ban creating structural phytogenic and probiotic demand that grows with livestock production volume. EU 2019/6 prophylactic antibiotic restriction creating regulatory-driven demand for probiotic, phytogenic, and organic acid alternatives to maintain production performance without antibiotic inputs.
  • Companion animal probiotic market growing from human gut health wellness culture extension to pet ownership. Pet humanisation extending human probiotic wellness culture to companion animal ownership — creating premium-priced veterinary-grade probiotic market serving dogs and cats.
  • Aquaculture intestinal health market growing from fish farming intensification and antibiotic restrictions in aquaculture. Salmon, shrimp, and tilapia aquaculture intensification creating intestinal health additive demand as antibiotic reduction in aquaculture creates production performance gap similar to terrestrial livestock.
  • Microbiome sequencing research creating scientific validation for next-generation probiotic strain selection and efficacy claims. Gut microbiome sequencing research enabling probiotic strain selection based on functional microbiome data — creating scientific differentiation above conventional empirical strain selection.
  • Post-weaning piglet and broiler chick market segments growing fastest from enteric disease prevention value. Post-weaning diarrhea in piglets and necrotic enteritis in broilers representing the highest-value enteric disease prevention targets — sustaining above-market intestinal health product demand in these production segments.
  • Enzyme products growing within intestinal health from feed efficiency improvement and nutrient bioavailability value. Phytase, xylanase, and protease enzyme products improving nutrient bioavailability and reducing feed cost within the intestinal health product category.

Market Segmentation: Animal Intestinal Health Market

By Mode of Delivery
  • Feed Additives
  • Water Additives
  • Oral Supplements
  • Tablets & Boluses
  • Powders
  • Liquid Formulations
  • Injectable
  • Other Modes of Delivery
By Function
  • Preventive Care
  • Disease Treatment
  • Growth Promotion
  • Gut Microbiome Modulation
  • Nutrient Absorption Enhancement
  • Immune System Support
  • Stress Management
  • Others
By Indication
  • Diarrhea
  • Enteric Infections
  • Dysbiosis
  • Inflammatory Bowel Disorders
  • Digestive Disorders
  • Nutritional Deficiencies
  • Others
By End User
  • Livestock Farmers
  • Pet Owners
  • Veterinary Hospitals & Clinics
  • Animal Nutrition Companies
  • Veterinary Pharmacies
  • Research & Academic Institutes
By Animal Type
  • Production Animals
    • Cattle
    • Swine
    • Poultry
    • Sheep & Goats
    • Aquaculture
    • Other Production Animals
  • Companion Animals
    • Canine (Dogs)
    • Feline (Cats)
    • Equine (Horses)
    • Birds
    • Rabbits
    • Reptiles
    • Other Companion Animals
By Product Type
  • Nutrition
    • Probiotics
    • Prebiotics
    • Postbiotics
    • Synbiotics
    • Phytogenics
    • Enzymes
    • Immunomodulators
    • Organic Acids
    • Yeast-Based Products
    • Amino Acids & Vitamins
    • Other Nutritional Products
  • Pharmaceuticals
    • Antibiotics
    • Antiparasitics
    • Anti-inflammatory Drugs
    • Antidiarrheal Agents
    • Electrolytes & Rehydration Solutions
    • Gastrointestinal Protectants
    • Other Pharmaceuticals
By End User
  • Biopharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Contract Development & Manufacturing Organizations (CDMOs/CMOs)
  • Academic & Research Institutions
  • Food & Beverage Companies
  • Industrial Biotechnology Companies
  • Government & Public Research Laboratories
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Animal Intestinal Health Market

  1. EU antimicrobial stewardship regulation creating structural non-antibiotic intestinal health alternative demand. EU 2019/6 and global AMR stewardship regulation driving structural demand for probiotic, phytogenic, and enzyme intestinal health alternatives.
  2. Pet humanisation creating structurally non-discretionary companion animal healthcare spending. Pet humanisation elevating companion animal healthcare to human medicine equivalence creates non-discretionary spending growing with pet ownership and income.
  3. One Health framework sustaining public investment in animal health independent of commercial cycles. One Health policy creating government funding for zoonotic surveillance, AMR stewardship, and food safety that supports animal health market growth.
  4. Global protein demand from emerging market growth driving farm animal production intensification. Emerging market protein consumption growth requiring food animal production intensification creating proportionate veterinary health product demand.
  5. Companion animal mAb therapeutics creating recurring monthly revenue above single-purchase pharmaceutical cycles. Monthly-dosed mAb therapeutics (Cytopoint, Librela, Solensia) generating recurring clinical revenue that compounds market growth above conventional product replacement.
  6. Asia-Pacific simultaneous pet ownership expansion and livestock intensification creating fastest-growing regional demand. Asia-Pacific growing fastest from dual companion animal and livestock market development driven by economic growth and urbanisation.

Regional Outlook: Animal Intestinal Health Market

  • North America: Dominant established market anchored by Zoetis’s approximately USD 9.5 billion 2025 revenue, IDEXX’s approximately 80-laboratory diagnostic network, and the world’s highest companion animal per-animal healthcare spending — driving product innovation adoption faster than any other regional market.
  • Europe: Significant established market where Boehringer Ingelheim Animal Health and Virbac operate under EU 2019/6 antimicrobial stewardship regulation — the world’s most stringent livestock antibiotic framework — driving vaccine and alternative product adoption across farm animal health.
  • Asia-Pacific: Fastest-growing regional market driven by China’s pet ownership boom, India’s livestock production intensification, and Southeast Asia’s growing veterinary care adoption. The region holds 60-plus percent of global livestock populations creating structural farm animal health demand growing proportionately with protein consumption.

Competitive Landscape: Animal Intestinal Health Market

Key Players: Zoetis Inc. (NYSE: ZTS), Elanco Animal Health (NYSE: ELAN), Boehringer Ingelheim Animal Health, Merck Animal Health, IDEXX Laboratories (NASDAQ: IDXX), Virbac, Vétoquinol, Ceva Santé Animale, Antech Diagnostics (Mars), Dechra Pharmaceuticals, Phibro Animal Health, and Norbrook Laboratories

Recent Developments

  • Elanco Animal Health’s FY2025 Annual Report filed with the SEC confirmed Elanco’s farm animal portfolio serving cattle, poultry, swine and sheep in more than 90 countries — with the company’s Go Beyond commitment to farmers and its mission of making life better for animals including ensuring health and safety of consumers while protecting the accessibility of affordable animal protein through effective intestinal health management.
  • Zoetis’ FY2025 Annual Report filed with the SEC confirmed broad-based Q4 2025 livestock product growth across all core species including cattle, fish and poultry in Zoetis’s International segment — demonstrating the geographic breadth and sustained commercial momentum of livestock health product demand including intestinal health products serving production performance and disease prevention objectives.
  • IDEXX Laboratories’ FY2025 Annual Report filed with the SEC confirmed IDEXX’s diagnostic laboratory services to biomedical research customers in North America, Europe, and Asia — including microbiome and enteric disease research in animal models — reflecting the scientific infrastructure that advances understanding of the animal gut microbiome and informs intestinal health product development.

Consultant POV

The Animal Intestinal Health Market’s 8.5% CAGR through 2035 from USD 5.2 billion in 2025 is structurally anchored in the most durable growth drivers in the life sciences sector — pet humanisation, food security investment, and One Health policy — each of which grows independently of economic cycles. Zoetis’s USD 9.5 billion 2025 revenue and 12 blockbuster-potential pipeline candidates, Elanco’s 90-plus country global footprint, and IDEXX’s continuous diagnostic innovation confirm that the animal intestinal health market’s 8.5% CAGR reflects a regulatory tailwind that is structural rather than cyclical — EU antimicrobial stewardship mandates and AMR awareness are permanent features of livestock production that will sustain demand for intestinal health alternatives through 2035 and beyond.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report